Commercially Available Gene Expression Assays as Predictive Tools for Adjuvant Radiotherapy? A Critical Review

Background: Gene expression assays are increasingly used for decision-making regarding adjuvant chemotherapy in patients with hormone receptor-positive, HER2-negative breast cancer. There are some clinical situations in which there is also a need for better prognostic and predictive markers to bette...

Full description

Saved in:
Bibliographic Details
Published inBreast care (Basel, Switzerland) Vol. 15; no. 2; pp. 118 - 127
Main Authors Krug, David, Baumann, René, Budach, Wilfried, Duma, Marciana Nona, Dunst, Jürgen, Feyer, Petra, Fietkau, Rainer, Haase, Wulf, Harms, Wolfgang, Hehr, Thomas, Piroth, Marc D., Sedlmayer, Felix, Souchon, Rainer, Wenz, Frederik, Sauer, Rolf
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger GmbH 01.04.2020
Subjects
Online AccessGet full text
ISSN1661-3791
1661-3805
DOI10.1159/000505656

Cover

More Information
Summary:Background: Gene expression assays are increasingly used for decision-making regarding adjuvant chemotherapy in patients with hormone receptor-positive, HER2-negative breast cancer. There are some clinical situations in which there is also a need for better prognostic and predictive markers to better estimate the amount of benefit from adjuvant radiotherapy. The rising availability of gene expression analyses prompts the question whether their results can also be used to guide clinical decisions regarding adjuvant radiation. Summary: Multiple studies suggest a correlation between results from gene expression assays and locoregional recurrence rates. Only few publications addressed the predictive value of results from gene expression analysis for the role of adjuvant radiotherapy in different settings. Key Messages: To date, the available evidence on the possible predictive value of gene expression assays for radiotherapy does not support their inclusion into the decision-making process for adjuvant radiation. This is due to methodological weaknesses and limitations regarding patient selection, the nonrandomized design of all studies in terms of radiotherapy use, and limited availability of tissue from prospective trials. Thus, utilization of the present knowledge for clinical indication of radiotherapy should be very cautious.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1661-3791
1661-3805
DOI:10.1159/000505656